Skip to main content

Andrew Berchuck, MD

Andrew Berchuck, MD
James M. Ingram Professor of Gynecologic Oncology
Campus Mail: 25171 Morris Bldg, Durham, NC 27710
Phone: (919) 684-3765
Email: berch001@mc.duke.edu

Dr. Andrew Berchuck is Director of the Duke Division of Gynecologic Oncology and holds the James M. Ingram Distinguished Professorship. He is a practicing oncologist who is actively involved in the surgical and chemotherapy management of women with ovarian, endometrial and lower genital tract cancers. This includes minimally invasive laparoscopic surgical approaches. He also has developed a research program that focuses on the molecular-genetic alterations involved in malignant transformation of the ovarian and endometrial epithelium. He has published over 300 peer-reviewed papers in these areas. The objectives of his research include 1) identification of ovarian cancer susceptibility polymorphisms through a population-based case-control molecular epidemiologic study, and 2) use of genomic approaches  to elucidate the molecular heterogenetity of ovarian cancer. Thirty fellows and residents have worked in his lab, several of whom are now funded investigators. His research efforts have been recognized nationally and he has received awards for best oral presentation at the annual meetings of both the Society of Gynecologic Oncology and the International Gynecologic Cancer Society. Dr. Berchuck was awarded the Barbara Thomason Ovarian Cancer Research Professorship by the American Cancer Society in 2006. He has served as editor of several books in the field including Principles and Practice of Gynecologic Oncology. Dr. Berchuck also has a major commitment to national activities, and was President of the Society of Gynecologic Oncology in 2008. He served as chair of the scientific advisory committee of the Ovarian Cancer Research Fund (http://www.ocrf.org) in New York City. Finally, he is also head of the steering committee of the international Ovarian Cancer Association Consortium (OCAC), a group of 50 case-control studies that are working together to identify ovarian cancer susceptibility polymorphisms (www.srl.cam.ac.uk/consortia/ocac/index.html).

Education and Training

  • M.D., Case Western Reserve University, 1980

Research

Dr Berchuck is interested in the molecular pathogenesis of ovarian and endometrial cancer. 

View Publications

Publications

Lopez-Acevedo, M, Zhang, C, Secord, AA, Lee, PS, Havrilesky, LJ, and Berchuck, A. "Predictors of failure to perform pelvic peritoneal cytology in endometrial cancer staging surgery." JOURNAL OF CLINICAL ONCOLOGY 30, no. 34 (December 1, 2012).

Full Text

Zhang, C, Secord, AA, Lee, PS, Havrilesky, LJ, and Berchuck, A. "Predictors of failure to perform pelvic peritoneal cytology in endometrial cancer staging surgery." Journal of clinical oncology : official journal of the American Society of Clinical Oncology 30, no. 34_suppl (December 2012): 201-.

Scholars@Duke

Secord, AA, Teoh, DK, Barry, WT, Yu, M, Broadwater, G, Havrilesky, LJ, Lee, PS, Berchuck, A, Lancaster, J, and Wenham, RM. "A phase I trial of dasatinib, an SRC-family kinase inhibitor, in combination with paclitaxel and carboplatin in patients with advanced or recurrent ovarian cancer." Clin Cancer Res 18, no. 19 (October 1, 2012): 5489-5498.

Full Text

Berchuck, A. "Genetic testing in ovarian cancer: getting better, and maybe not just for disease susceptibility anymore." Obstet Gynecol 120, no. 2 Pt 1 (August 2012): 221-222.

Full Text

Alvarez Secord, A, Berchuck, A, Higgins, RV, Nycum, LR, Kohler, MF, Puls, LE, Holloway, RW, Lewandowski, GS, Valea, FA, and Havrilesky, LJ. "A multicenter, randomized, phase 2 clinical trial to evaluate the efficacy and safety of combination docetaxel and carboplatin and sequential therapy with docetaxel then carboplatin in patients with recurrent platinum-sensitive ovarian cancer." Cancer 118, no. 13 (July 1, 2012): 3283-3293.

Full Text

Charbonneau, B, White, KL, Schildkraut, JM, Palmieri, RT, Iversen, E, Berchuck, A, Vierkant, RA, Rider, DN, Cicek, MS, Sutphen, R, Birrer, MJ, Pharoah, PP, Song, H, Tyrer, J, Gayther, SA, Ramus, SJ, Wentzensen, N, Yang, HP, Garcia-Closas, M, Phelan, CM, Cunningham, JM, Fridley, BL, Sellers, TA, and Goode, EL. "Abstract 2603: Subtype-specific ovarian cancer risk associated with SNPs in IL1A :." Cancer Research 72, no. 8 Supplement (April 15, 2012): 2603-2603.

Full Text

Huang, Z, Lowery, WJ, Berchuck, A, and Murphy, SK. "Abstract 5363: Aggregation rather than monoclonal expansion explains ovarian cancer spheroid formation." Cancer Research 72, no. 8 Supplement (April 15, 2012): 5363-5363.

Full Text

Okamoto, T, Yamaguchi, K, Huang, Z, Whitaker, R, Konishi, I, Berchuck, A, and Murphy, SK. "Abstract LB-87: Methylated-mediated repression of ZNF154 in ovarian cancer is associated with poor overall survival." Cancer Research 72, no. 8 Supplement (April 15, 2012): LB-87-LB-87.

Full Text

Pearce, CL, Templeman, C, Rossing, MA, Lee, A, Near, AM, Webb, PM, Nagle, CM, Doherty, JA, Cushing-Haugen, KL, Wicklund, KG, Chang-Claude, J, Hein, R, Lurie, G, Wilkens, LR, Carney, ME, Goodman, MT, Moysich, K, Kjaer, SK, Hogdall, E, Jensen, A, Goode, EL, Fridley, BL, Larson, MC, Schildkraut, JM, Palmieri, RT, Cramer, DW, Terry, KL, Vitonis, AF, Titus, LJ, Ziogas, A, Brewster, W, Anton-Culver, H, Gentry-Maharaj, A, Ramus, SJ, Anderson, AR, Brueggmann, D, Fasching, PA, Gayther, SA, and Huntsman, DG et al. "Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies." Lancet Oncol 13, no. 4 (April 2012): 385-394.

Full Text

Bolton, KL, Ganda, C, Berchuck, A, Pharaoh, PDP, and Gayther, SA. "Role of common genetic variants in ovarian cancer susceptibility and outcome: progress to date from the Ovarian Cancer Association Consortium (OCAC)." J Intern Med 271, no. 4 (April 2012): 366-378. (Review)

Full Text

Pages